Drugs / Live Attenuated Varicella Virus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00830648 | Jan → Oct 2009 | chickenpox | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live Attenuated Varicella Virus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00830648 ↗ |
| Modality | Vaccine | “Live Attenuated Varicella Virus Vaccine” NCT00830648 ↗ |
| Route | Subcutaneous | “0.5 mL, Subcutaneous” NCT00830648 ↗ |